{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:57Z","timestamp":1784977257437,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhangzhou City Natural Science Foundation Joint Project","award":["ZZ2025LH47"],"award-info":[{"award-number":["ZZ2025LH47"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04270-3","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:02:45Z","timestamp":1772564565000},"page":"3548-3557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality analysis of adverse events associated with degarelix: a real-world study from the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1007","volume":"28","author":[{"given":"Xiaojuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huishan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8413-3677","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"20","key":"4270_CR1","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","volume":"43","author":"R Garje","year":"2025","unstructured":"Garje R, Riaz IB, Naqvi SAA,\u00a0Rumble RB, Taplin ME, Kungel TM, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update. J Clin Oncol: Off J Am Soc Clin Oncol. 2025;43(20):2311\u201334.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"16","key":"4270_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333(16):1433\u201346.","journal-title":"JAMA"},{"issue":"2","key":"4270_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ncpendmet0399","volume":"3","author":"JB Engel","year":"2007","unstructured":"Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157\u201367.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"11","key":"4270_CR4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531\u20138.","journal-title":"BJU Int"},{"issue":"2","key":"4270_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.euo.2021.07.002","volume":"5","author":"R Sari Motlagh","year":"2022","unstructured":"Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, et al. The efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. Eur Urol Oncol. 2022;5(2):138\u201345.","journal-title":"Eur Urol Oncol"},{"issue":"16","key":"4270_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, S\u00f8rensen PS, et al. cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295\u2013307.","journal-title":"Circulation"},{"key":"4270_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1266890","volume":"14","author":"T Yuan","year":"2023","unstructured":"Yuan T, Li F, Hou Y, Guo H. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study. Front Pharmacol. 2023;14:1266890.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4270_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40360-024-00821-y","volume":"25","author":"T Zou","year":"2024","unstructured":"Zou T, Li Z, Wang T, Deng S, Wang S, Hua Y. A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab[J]. BMC Pharmacol Toxicol. 2024;25(1):97.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"12","key":"4270_CR9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1159\/000540542","volume":"102","author":"Z Liu","year":"2024","unstructured":"Liu Z, Wu D, Ke C, Nian Q, Chen Y, Huang Y, et al. Real-world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System database for asciminib. Oncology. 2024;102(12):1084\u201396.","journal-title":"Oncology"},{"issue":"1","key":"4270_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","volume":"48","author":"L Huang","year":"2014","unstructured":"Huang L, Guo T, Zalkikar JN, Tiwari RC. A review of statistical methods for safety surveillance. Ther Innov Regul Sci. 2014;48(1):98\u2013108.","journal-title":"Ther Innov Regul Sci"},{"key":"4270_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y,\u00a0Wu P, Zhang Q. A real-world disproportionality analysis of Olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. 2022;14:789\u2013802.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"4270_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","volume":"23","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Ding Y, Shu Y, Chen J. A real-world disproportionality analysis of Rucaparib: post-marketing pharmacovigilance data. BMC Cancer. 2023;23(1):745.","journal-title":"BMC Cancer"},{"issue":"3","key":"4270_CR13","first-page":"420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM.\u00a0A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel, Switzerland). 2022;10(3):420.","journal-title":"Healthcare (Basel, Switzerland)"},{"issue":"1","key":"4270_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/nyas.15187","volume":"1538","author":"B Grant","year":"2024","unstructured":"Grant B, Hyams E, Davies R, Minhas S, Jayasena CN. Androgen abuse: risks and adverse effects in men. Ann N Y Acad Sci. 2024;1538(1):56\u201370.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"4270_CR15","doi-asserted-by":"publisher","first-page":"2581656","DOI":"10.1080\/13685538.2025.2581656","volume":"28","author":"Y Chai","year":"2025","unstructured":"Chai Y, Yao Z, Zhou Z, Zhang Y. Effectiveness and safety of degarelix compared to GnRH agonists for prostate cancer: a systematic review and meta-analysis. Aging male: Off J Int Soc Study Aging Male. 2025;28(1):2581656.","journal-title":"Aging male: Off J Int Soc Study Aging Male"},{"issue":"9","key":"4270_CR16","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/ijc.33397","volume":"148","author":"G George","year":"2021","unstructured":"George G, Garmo H, Scailteux L, Balusson F, De Coster G, De Schutter H, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases. Int J Cancer. 2021;148(9):2203\u201311.","journal-title":"Int J Cancer"},{"issue":"6","key":"4270_CR17","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","volume":"202","author":"D Margel","year":"2019","unstructured":"Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202(6):1199\u2013208.","journal-title":"J Urol"},{"issue":"5","key":"4270_CR18","first-page":"1377","volume":"23","author":"T Maeda","year":"2015","unstructured":"Maeda T, Kosaka T, Honda A, Okata U, Hayakawa N, Ito Y, et al. Evaluation of histopathological findings at the injection site following degarelix administration. Support Care Cancer: Off J Multinatl Assoc Support Care Cancer. 2015;23(5):1377\u201381.","journal-title":"Support Care Cancer: Off J Multinatl Assoc Support Care Cancer"},{"issue":"6","key":"4270_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","volume":"203","author":"DP Leong","year":"2020","unstructured":"Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109\u201316.","journal-title":"J Urol"},{"issue":"48","key":"4270_CR20","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889\u201397.","journal-title":"Eur Heart J"},{"issue":"3","key":"4270_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/ehjcvp\/pvab005","volume":"8","author":"F Cirne","year":"2022","unstructured":"Cirne F, Aghel N, Petropoulos J, Klotz L, Lenihan DJ, Saad F, et al. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. Eur Heart J Cardiovas Pharmacother. 2022;8(3):253\u201362.","journal-title":"Eur Heart J Cardiovas Pharmacother"},{"issue":"6","key":"4270_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121(6):833\u201340.","journal-title":"Circulation"},{"issue":"6","key":"4270_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/UPJ.0000000000000878","volume":"12","author":"EV Li","year":"2025","unstructured":"Li EV, Ho AY, Bennett RT, Aguiar J, Wong C, Suk-Ouichai C, et al. Adverse cardiovascular outcomes of individuals treated with androgen deprivation therapy. Urol Pract. 2025;12(6):743\u201351.","journal-title":"Urol Pract"},{"key":"4270_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104817","volume":"97","author":"K David","year":"2023","unstructured":"David K, Devos G, Narinx N, Antonio L, Devlies W, Deboel L, et al. Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor - substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial. EBioMedicine. 2023;97:104817.","journal-title":"EBioMedicine"},{"issue":"6","key":"4270_CR25","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11154-022-09738-5","volume":"23","author":"K David","year":"2022","unstructured":"David K, Narinx N, Antonio L, Evenepoel P, Claessens F, Decallonne B, et al. Bone health in ageing men. Rev Endocr Metab Disord. 2022;23(6):1173\u2013208.","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"4270_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000652","volume":"5","author":"D Santini","year":"2020","unstructured":"Santini D, Berruti A, Di Maio M,\u00a0Procopio G, Bracarda S, Ibrahim T, et al. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. ESMO open. 2020;5(2):e652.","journal-title":"ESMO open"},{"issue":"4","key":"4270_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.reumae.2018.09.011","volume":"15","author":"A Naranjo Hern\u00e1ndez","year":"2019","unstructured":"Naranjo Hern\u00e1ndez A, D\u00edaz Del Campo Fontecha P, Aguado Ac\u00edn MP, Arboleya Rodr\u00edguez L, Casado Burgos E, Casta\u00f1eda S, et al. Recommendations by the Spanish society of rheumatology on osteoporosis. Reumatolog\u00eda Cl\u00ednica (English Edition). 2019;15(4):188\u2013210.","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"issue":"43","key":"4270_CR28","doi-asserted-by":"publisher","first-page":"75646","DOI":"10.18632\/oncotarget.17980","volume":"8","author":"L Cianferotti","year":"2017","unstructured":"Cianferotti L, Bertoldo F, Carini M, Kanis JA, Lapini A, Longo N, et al. The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget. 2017;8(43):75646\u201363.","journal-title":"Oncotarget"},{"issue":"1","key":"4270_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5534\/wjmh.210061","volume":"40","author":"E Casado","year":"2022","unstructured":"Casado E, Borque-Fernando A, Caama\u00f1o M, Gra\u00f1a J, Mu\u00f1oz-Rodr\u00edguez J, Morote J. Multidisciplinary consensus on the prevention and treatment of osteoporosis and fragility fractures in patients with prostate cancer receiving androgen-deprivation therapy. World J Mens Health. 2022;40(1):74\u201386.","journal-title":"World J Mens Health"},{"issue":"10","key":"4270_CR30","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.6004\/jnccn.2020.7576","volume":"18","author":"J Hu","year":"2020","unstructured":"Hu J, Aprikian AG, Vanhuyse M,\u00a0Dragomir A. Contemporary population-based analysis of bone mineral density testing in men initiating androgen deprivation therapy for prostate cancer. J Natl Compr Canc Netw. 2020;18(10):1374\u201381.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"4270_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","volume":"7","author":"P Conte","year":"2022","unstructured":"Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO open. 2022;7(2):100404.","journal-title":"ESMO open"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04270-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04270-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04270-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:02Z","timestamp":1784975342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04270-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4270"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04270-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study is a secondary analysis of publicly available summary statistics and requires no specific ethical approval.","order":2,"name":"Ethics","label":"Ethical approval and Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}